{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=BRCA2+Gene",
    "query": {
      "condition": "BRCA2 Gene"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 56,
    "total_pages": 6,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=BRCA2+Gene&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-23T18:13:00.874Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03546972",
      "title": "Diabetes Prevention Program With or Without Hunger Training in Helping to Lower Breast Cancer Risk in Obese Participants",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Deleterious BRCA1 Gene Mutation",
        "Deleterious BRCA2 Gene Mutation",
        "Ductal Breast Carcinoma In Situ",
        "Obesity",
        "Overweight",
        "Premalignant Lesion"
      ],
      "interventions": [
        {
          "name": "Behavioral, Psychological or Informational Intervention",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "70 Years",
        "sex": "FEMALE",
        "summary": "30 Years to 70 Years · Female only"
      },
      "enrollment_count": 51,
      "start_date": "2017-12-17",
      "completion_date": "2026-11-30",
      "has_results": false,
      "last_update_posted_date": "2026-04-15",
      "last_synced_at": "2026-07-23T18:13:00.874Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03546972"
    },
    {
      "nct_id": "NCT05787587",
      "title": "A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced or Metastatic Solid Tumors",
        "Breast Cancer",
        "Ovarian Cancer",
        "Prostate Cancer",
        "Endometrial Cancer",
        "Colorectal Cancer",
        "Head and Neck Cancers",
        "Extensive Stage Small Cell Lung Cancer (ES-SCLC)",
        "NSCLC"
      ],
      "interventions": [
        {
          "name": "IDE-161",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "IDEAYA Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 216,
      "start_date": "2023-04-18",
      "completion_date": "2027-05",
      "has_results": false,
      "last_update_posted_date": "2026-07-13",
      "last_synced_at": "2026-07-23T18:13:00.874Z",
      "location_count": 27,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 22 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05787587"
    },
    {
      "nct_id": "NCT00776958",
      "title": "Lynne Cohen Consortium Project: Multi-Center Database/Registry",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Ovarian Cancer",
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Questionnaire",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 176,
      "start_date": "2008-07",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2014-07-31",
      "last_synced_at": "2026-07-23T18:13:00.874Z",
      "location_count": 4,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • New York, New York + 1 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00776958"
    },
    {
      "nct_id": "NCT03442556",
      "title": "Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "ATM Gene Mutation",
        "BRCA1 Gene Mutation",
        "BRCA2 Gene Mutation",
        "Castration Levels of Testosterone",
        "Castration-Resistant Prostate Carcinoma",
        "Homologous Recombination Deficiency",
        "Prostate Carcinoma Metastatic in the Bone",
        "PSA Level Greater Than or Equal to Two",
        "PSA Progression",
        "Stage IV Prostate Adenocarcinoma AJCC v7"
      ],
      "interventions": [
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Rucaparib Camsylate",
          "type": "DRUG"
        },
        {
          "name": "Rucaparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 18,
      "start_date": "2018-08-24",
      "completion_date": "2025-06-04",
      "has_results": false,
      "last_update_posted_date": "2025-06-12",
      "last_synced_at": "2026-07-23T18:13:00.874Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03442556"
    },
    {
      "nct_id": "NCT02154633",
      "title": "Lessons Learned From the Family Gene Toolkit",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Women With BRCA 1 or BRCA 2 Mutation",
        "Non-tested Female Family Members"
      ],
      "interventions": [
        {
          "name": "Family Gene Toolkit",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Delayed Family Gene Toolkit",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Michigan",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 13,
      "start_date": "2010-09-30",
      "completion_date": "2017-03-31",
      "has_results": false,
      "last_update_posted_date": "2020-02-25",
      "last_synced_at": "2026-07-23T18:13:00.874Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02154633"
    },
    {
      "nct_id": "NCT05498272",
      "title": "Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer",
        "BRCA1 Mutation",
        "BRCA2 Mutation",
        "Prostatic Adenocarcinoma",
        "High-Risk Cancer"
      ],
      "interventions": [
        {
          "name": "Olaparib",
          "type": "DRUG"
        },
        {
          "name": "LHRH agonist",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rana McKay, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 32,
      "start_date": "2023-02-01",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-07-10",
      "last_synced_at": "2026-07-23T18:13:00.874Z",
      "location_count": 6,
      "location_summary": "La Jolla, California • Baltimore, Maryland • New York, New York + 2 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05498272"
    },
    {
      "nct_id": "NCT06022029",
      "title": "A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Triple Negative Breast Cancer",
        "Diffuse Large B Cell Lymphoma",
        "Follicular Lymphoma",
        "Lymphoma, Non-Hodgkin",
        "Mantle Cell Lymphoma",
        "Bladder Cancer",
        "Uveal Melanoma, Recurrent",
        "Cervix Cancer",
        "Carcinoma in Situ",
        "Head and Neck Squamous Cell Carcinoma",
        "Skin Cancer",
        "Metastatic Cancer",
        "Tumor, Solid",
        "Tumor Recurrence"
      ],
      "interventions": [
        {
          "name": "ONM-501",
          "type": "DRUG"
        },
        {
          "name": "Cemiplimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "OncoNano Medicine, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 168,
      "start_date": "2023-10-13",
      "completion_date": "2026-08-29",
      "has_results": false,
      "last_update_posted_date": "2025-12-24",
      "last_synced_at": "2026-07-23T18:13:00.874Z",
      "location_count": 9,
      "location_summary": "Los Angeles, California • Tamarac, Florida • Canton, Ohio + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Tamarac",
          "state": "Florida"
        },
        {
          "city": "Canton",
          "state": "Ohio"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06022029"
    },
    {
      "nct_id": "NCT01945775",
      "title": "A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Neoplasms",
        "BRCA 1 Gene Mutation",
        "BRCA 2 Gene Mutation"
      ],
      "interventions": [
        {
          "name": "talazoparib",
          "type": "DRUG"
        },
        {
          "name": "Physician's-Choice",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 431,
      "start_date": "2013-10-14",
      "completion_date": "2021-03-05",
      "has_results": true,
      "last_update_posted_date": "2022-01-20",
      "last_synced_at": "2026-07-23T18:13:00.874Z",
      "location_count": 207,
      "location_summary": "Flagstaff, Arizona • Scottsdale, Arizona • Antioch, California + 136 more",
      "locations": [
        {
          "city": "Flagstaff",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Antioch",
          "state": "California"
        },
        {
          "city": "Antioch",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01945775"
    },
    {
      "nct_id": "NCT02760849",
      "title": "Surgery in Preventing Ovarian Cancer in Patients With Genetic Mutations",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Deleterious BARD1 Gene Mutation",
        "Deleterious BRCA1 Gene Mutation",
        "Deleterious BRCA2 Gene Mutation",
        "Deleterious BRIP1 Gene Mutation",
        "Deleterious EPCAM Gene Mutation",
        "Deleterious MLH1 Gene Mutation",
        "Deleterious MSH2 Gene Mutation",
        "Deleterious MSH6 Gene Mutation",
        "Deleterious PALB2 Gene Mutation",
        "Deleterious PMS2 Gene Mutation",
        "Deleterious RAD51C Gene Mutation",
        "Deleterious RAD51D Gene Mutation",
        "Hereditary Breast and Ovarian Cancer Syndrome",
        "Premenopausal"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Oophorectomy",
          "type": "PROCEDURE"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Salpingectomy",
          "type": "PROCEDURE"
        },
        {
          "name": "Salpingo-Oophorectomy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "30 Years to 50 Years · Female only"
      },
      "enrollment_count": 374,
      "start_date": "2016-05-02",
      "completion_date": "2041-05-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-15",
      "last_synced_at": "2026-07-23T18:13:00.874Z",
      "location_count": 9,
      "location_summary": "Chicago, Illinois • Boston, Massachusetts • Rochester, Minnesota + 5 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02760849"
    },
    {
      "nct_id": "NCT02783664",
      "title": "Evaluating the Effects of Genetic Testing on Patients' Stress Levels",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Questionnaires to Evaluate Anxiety Related to Genetic Testing",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Medical College of Wisconsin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 164,
      "start_date": "2016-07",
      "completion_date": "2027-07",
      "has_results": false,
      "last_update_posted_date": "2025-10-09",
      "last_synced_at": "2026-07-23T18:13:00.874Z",
      "location_count": 1,
      "location_summary": "Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02783664"
    }
  ]
}